A Phase 2 interventional study of K-877 IR 0.2 mg/day and K-877 CR 0.4 mg/day in Dyslipidemias, sponsored by Kowa Company, Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Kowa Company, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Dyslipidemias by Kowa Company, Ltd. — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Kowa Company, Ltd..
Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., this one is the 16th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 2, and was the 17th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 20 studies in Dyslipidemias by Kowa Company, Ltd. is open now. The open studies under Dyslipidemias, anywhere →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 290 across the 20 interventional studies. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
Kowa Company, Ltd. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to compare the efficacy, safety, and pharmacokinetics of K-877 controlled release tablets with a current normal K-877 tablet in dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day
Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day
Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day
Period1:K-877 IR 0.2 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day
Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day
Period1:K-877 CR 0.4 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.4 mg/day
Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (pre-meal)
Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day
Period1:K-877 CR 0.4 mg/day, Period2:K-877 CR 0.8 mg/day (postprandial)
Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day
Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (pre-meal)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day
Period1:K-877 CR 0.8 mg/day, Period2:K-877 IR 0.2 mg/day (postprandial)
Drug: K-877 IR 0.2 mg/day · Drug: K-877 CR 0.8 mg/day
Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (pre-meal)
Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day
Period1:K-877 CR 0.8 mg/day, Period2:K-877 CR 0.4 mg/day (postprandial)
Drug: K-877 CR 0.4 mg/day · Drug: K-877 CR 0.8 mg/day
Drug page: Pemafibrate
K-877 IR 0.1 mg tablet
Also known as: Pemafibrate
Drug page: Pemafibrate
K-877 CR 0.4 mg tablet
Also known as: Pemafibrate
Drug page: Pemafibrate
Two K-877 CR 0.4 mg tablet
Also known as: Pemafibrate
Efficacy: % change from baseline in fasting serum TG(mg/dL)
Time frame: 4 week after administration in each period
% change from baseline in fasting HDL-C levels(mg/dL)
Time frame: 4 week after administration in each period
% change from baseline in fasting LDL-C levels(mg/dL)
Time frame: 4 week after administration in each period
% change from baseline in fasting non-HDL-C levels(mg/dL)
Time frame: 4 week after administration in each period
% change from baseline in fasting Total Cholesterol levels(mg/dL)
Time frame: 4 week after administration in each period
Ran from Sep 2019 to primary completion in Dec 2019, 3 months.
Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 3 months is below that.
Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemafibrate